Piper Sandler Backs Palisade Bio Ahead of Key Crohn’s Data
Piper Sandler starts coverage on Palisade Bio with an Overweight rating and a $25 target, citing strong potential for its Crohn’s disease drug PALI-2108.
/ 1662 items
#XY↓
BTIG Cuts Organogenesis Confidence on CMS Policy Delay
BTIG maintains $9 price target on Organogenesis but reduces 2026 confidence after CMS delays skin substitute coverage rules, creating regulatory uncertainty for the wound care company.
Can-Fite Secures Brazilian Patent for Sexual Dysfunction Treatment
Can-Fite BioPharma receives Brazilian patent protection for its A3 adenosine receptor agonist drug targeting sexual dysfunction, expanding its presence in Latin America's pharmaceutical market.
H.C. Wainwright Starts Coverage on Inhibikase Therapeutics With Buy Rating
H.C. Wainwright begins coverage of Inhibikase Therapeutics with a Buy rating and $8 target, citing strong prospects for its Phase 3 PAH drug IKT-001.
Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.
FDA Reaffirms Proteinuria Endpoint for FSGS: Positive Signal for Travere Therapeutics
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.